The importance of biologicals in the treatment of SoJIA;Die Bedeutung von Biologika bei der Therapie der SoJIA (Morbus Still)

Zeitschrift fur Rheumatologie

Volumn 69, Issue 6, 2010, Pages 505-515

  Duckers G ^a   Niehues, T ^a  

^a HELIOS KLINIKUM KREFELD   (Germany)

Author keywords

Biologicals; ITF2357; Systemic onset juvenile idiopathic arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CANAKINUMAB; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL RESEARCH; DATA ANALYSIS; DISEASE REGISTRY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EFFECTOR CELL; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MEDLINE; METHODOLOGY; NONHUMAN; PROTEIN TARGETING; REVIEW; SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS; TREATMENT INDICATION; TREATMENT RESPONSE;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL PRODUCTS; CHILD; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; INTERLEUKIN-1; INTERLEUKIN-1BETA; INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956339298     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-010-0635-z     Document Type: Review

References (28)

1. Ballow M (2005) -ximab this and -zumab that! Has the magic bullet arrived in the new millennium of medicine and science? J Allergy Clin Immunol 116:738-743
2. Cassidy JT, Petty RE (2005) Juvenile idiopathic rheumatic arthritis. WB Saunders, Philadelphia
3. De Benedetti F, Massa M, Robbioni P et al (1991) Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 34:1158-1163
4. Gattorno M, Piccini A, Lasiglie D et al (2008) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58:1505-1515
5. Guellac N, Niehues T (2008) Interdisciplinary and evidence-based treatment guideline for juvenile idiopathic arthritis. Klin Padiatr 220:392-402
6. Horneff G, De Bock F, Foeldvari I et al (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 68:519-525
7. Horneff G, Hospach T, Dannecker G et al (2010) Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDAs report regarding malignancies in anti-TNF-treated patients from. Z Rheumatol [Epub ahead of print]
8. Horneff G, Schmeling H, Biedermann T et al (2004) The German Etanercept Registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63:1638-1644
9. Ilowite N, Porras O, Reiff A et al (2009) Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 28:129-137
10. Lehman TJ (2008) Are withdrawal trials in paediatric rheumatic disease helpful? Lancet 372:348-350
11. Lequerre T, Quartier P, Rosellini D et al (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67:302-308
12. Lovell DJ, Giannini EH, Kimura Y et al (2007) Preliminary evidence for sustained bioactivity of IL-1 trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis. Arthritis Rheum 56:S514
13. Lovell DJ, Giannini EH, Kimura Y et al (2009) Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (SJIA). Arthritis Rheum 60 (Suppl):S768 (abstr 2053)
14. Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763-769
15. Lovell DJ, Ruperto N, Goodman S et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359:810-820
16. Macaubas C, Nguyen K, Deshpande C et al (2010) Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states. Clin Immunol 134:206-216
17. Pascual V, Allantaz F, Arce E et al (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201:1479-1486
18. Prince FH, Twilt M, Ten Cate R et al (2009) Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch National Register. Ann Rheum Dis 68:635-641
19. Quartier P, Taupin P, Bourdeaut F et al (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48:1093-1101
20. Ruperto N, Lovell DJ, Cuttica R et al (2007) A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56:3096-3106
21. Ruperto N, Lovell DJ, Quartier P et al (2010) Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum [Epub ahead of print]
22. Ruperto N, Lovell DJ, Quartier P et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372:383-391
23. Ruperto N, Quartier P, Wulffraat N et al (2009) A phase II trial with canakinumab (ACZ885), a new IL-1-beta blocking monoclonal antibody, to evaluate safety and preliminary efficacy in children with systemic juvenile idiopathic arthritis. Ann Rheum Dis 68:170
24. Vojinovic J, Dinarello CA, Furlan A et al (2009) Safety and efficacy of oral ITF2357 in patients with active systemic onset juvenile idiopathic arthritis. Cytokine 48:93-94
25. Wittkowski H, Frosch M, Wulffraat N et al (2008) S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 58:3924-3931
26. Woo P (2006) Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2:28-34
27. Woo P, Wilkinson N, Prieur AM et al (2005) Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 7:R1281-R1288
28. Yokota S, Imagawa T, Mori M et al (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371:998-1006